Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)

NCT03571321 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT03571321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03571321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Recruiting
Start date
May 28, 2019
Completion date
September 5, 2027
Enrollment
15 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, all, all, childhood